SĀPH™ DRUG DELIVERY PLATFORM
SĀPH™ (Pronounced safe) is a biodegradable, peptide-based, nanofibrous hydrogel designed to control drug delivery as well as serve as a template for new drug development. The SĀPH™ platform is capable of simultaneous delivery of large and small molecular weight, hydrophilic or hydrophobic compounds, as well as cellular and biological based therapies. Matrx is developing new, branded products, employing SĀPH™ technology for off-patent drugs across several therapeutic areas, as well as constructing new drugs for IND submissions. Matrx’s proprietary SĀPH™ products are focused on the treatment of cancer, ocular and vascular diseases.
SĀPH™ as ACTIVE TEMPLATE FOR NEW PRODUCT DEVELOPMENT
Matrx expands its product capabilities and intellectual property offering through utility of the SĀPH™ technology to serve as a template for new drug development, thereby generating a fully active peptidyl matrix comprised of novel compound. Conjugation or direct continued synthesis of bioactive components onto the SĀPH™ backbone, provides multi-domain peptide advantages of SAPH™ to attached molecules thereby conferring SĀPH™ properties such as self-assembly, stability, controlled, and sustained release kinetics, facilitating regional application and response. Rather then simply delivering active components, in this approach the matrix itself serves as the active drug molecule, providing a biodegradable, sustained delivery platform with opportunity for new IP. Toward this aim Matrx has developed/licensed MTX61, a multidomain peptide (MDP)-based molecule for pro-angiogenesis and treatment of vascular related diseases.